Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer

Abstract

BackgroundThe clinical stage of the disease at diagnosis often determines the prognosis and survival rate of a patient with pancreatic cancer. Early symptoms of pancreatic cancer are often not obvious on imaging (ultrasound, computed tomography (CT), and so on), and when patients present with weight loss, jaundice and abdominal pain and other symptoms, they are usually already in the advanced stages of pancreatic cancer. However, the examination of combined tumor markers might improve their sensitivity or specificity in aiding diagnosis.MethodsTwelve tumor markers including AFP, CEA, NSE, CA125, CA15-3, CA242, CA19-9, PSA, f-PSA, FER, β-HCG and HGH were measured by the protein biochip detection in serum in 235 pancreatic cancer patients, 230 benign pancreatic disease patients and 240 healthy people.ResultsPositive detection rates of tumor markers were: CA19-9 (49.3%), CA125 (45.1%), FER (44.2%), CA242 (42.5%), CEA (38.6%), CA15-3 (36.7%), β-HCG (29.6%), AFP (24.5%), NSE (18.2%), PSA (19.5%), f-PSA (9.4%) and HGH (8.7%) respectively. There was significant difference in CA19-9, NSE, CEA, CA242 and CA125 by multi-tumor marker protein biochip detection among patients with cancer, benign disease and healthy people (P <0.05). The positive rate of 5 tumor markers was 94.9%, and this was much higher than that of any single marker.ConclusionThe detection of CA19-9, NSE, CEA, CA242 and CA125 in the multi-tumor marker protein biochip system is helpful in the diagnosis of pancreatic cancer.

Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy

“…In recent years, due to the constant depth of basic and clinical research, and advance in laboratory, endoscope, imaging techniques and equipments, especially the development of molecular biological techniques, the early detection level of malignant tumors in the digestive system have been improved greatly and more than 10 kinds of serum tumor markers for pancreatic cancer have been widely applied in clinic such as CA19-9, CEA, CA125, CA242, etc. ( Liu et al, 2014). However, there exist limitations such as low sensitivity, and poor specificity (Duraker et al, 2007).…”

“…The single detection of tumor markers lacks enough sensitivity and specificity to the diagnosis of pancreatic cancer. In recent years, researches were found that tumor markers such as CA19-9, CEA, CA125 and CA242 are of great significance to the early detection, treatment monitoring and prognosis assessment of pancreatic cancer (Liu et al, 2014). Therefore, this study explored the applicative value of joint detection of CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis assessment for patients with pancreatic cancer treated by concurrent chemoradiotherapy by analyzing the the expression levels of tumor markers in patients with pancreatic cancer.…”

The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC)

“…Certain studies have indicated that the serum levels of individual biomarkers, such as CA125, CEA, CA19-9, and CA242 are not associated with tumor size (8). However, patients with high expression levels of these markers presented with late-stage disease, which demonstrated that a comprehensive assessment of various biomarkers, to provide more biological information, was necessary (8,31,43). In previous studies, the multi-analysis of different biomarkers [CA19-9, neuron specific enolase (NSE), CEA, CA242, CA125, circulating tumor cells and ctDNA] was more useful in the diagnosis and prognosis of PC, and was superior to that of any single biomarker (75,76).…”

“…hepatobiliary disease and renal failure are commonly associated with false-positive results (43,51). Compared to patients with benign jaundice, patients with malignant jaundice have higher levels of CA19-9, which do not significantly decrease even after drainage (52).…”

“…In addition, the follow-up period is sometimes inadequate to treat metastasis effectively. Studies have reported that the measurement of a series of tumor markers [CA19-9, CA125, carcinoembryonic antigen (CEA), alpha-fetoprotein (AFp), CA242, CA72-4, CA50, CA15-3, and the beta-subunit of human chorionic gonadotropin (hCG-β)] improves the early diagnosis of cancer (36,43). CA125/MUC16 is aberrantly expressed in various types of cancer, and it can promote proliferation, migration and metastasis by facilitating metastatic and invasive gene transcription (23,44,45).…”